{
	"add": {
		"doc": {
			"id": "84b7656e6ea32b24309b341c298d40cc7fb7d9bc358834cf43977556fb9f4e23",
			"url": "https://upload.wikimedia.org/wikipedia/commons/thumb/0/03/Ovary_cancer_world_map_-_Death_-_WHO2004.svg/220px-Ovary_cancer_world_map_-_Death_-_WHO2004.svg.png",
			"previous": " Ovarian cancer frequently recurs after treatment If a recurrence occurs in advanced disease it typically occurs within 18 months of initial treatment 18 months progression free survival Recurrences can be treated but the disease free interval tends to shorten and chemoresistance increases with each recurrence 10 Low malignant potential tumors rarely relapse even when fertility sparing surgery is the treatment of choice 15 of LMP tumors relapse after unilateral surgery in the previously unaffected ovary and they are typically easily treated with surgery More advanced tumors may take up to 20 years to relapse if they relapse at all and are only treated with surgery unless the tumor has changed its histological characteristics or grown very quickly In these cases and when there is significant ascites chemotherapy may also be used 14 ",
			"after": " Globally as of 2010 about 160 000 people died from ovarian cancer up from 113 000 in 1990 57 As of 2014 more than 220 000 diagnoses of epithelial ovarian cancer were made yearly 10 In 2010 in the United States an estimated 21 880 new cases were diagnosed and 13 850 women died of ovarian cancer Around 1800 of the new diagnoses were sex cord or stromal tumors 11 In the United Kingdom as of 2014 approximately 7 000 7 100 yearly diagnoses were made and 4 200 deaths occurred 10 16 It is the 5th most common cancer in UK women Ovarian cancer is most commonly diagnosed after menopause 16 ",
			"color": "orange|0.37616 dark|0.35825 orange|0.35825 yellow|0.13116 gold|0.096199 sandy|0.012061 brown|0.012061 khaki|0.0073745 orange|0.0041976 red|0.0041976  ",
			"after_weights": " Globally|1 as|0.99107 of|0.98214 2010|0.97321 about|0.96429 160|0.95536 000|0.94643 people|0.9375 died|0.92857 from|0.91964 ovarian|0.91071 cancer|0.90179 up|0.89286 from|0.88393 113|0.875 000|0.86607 in|0.85714 1990|0.84821 57|0.83929 As|0.83036 of|0.82143 2014|0.8125 more|0.80357 than|0.79464 220|0.78571 000|0.77679 diagnoses|0.76786 of|0.75893 epithelial|0.75 ovarian|0.74107 cancer|0.73214 were|0.72321 made|0.71429 yearly|0.70536 10|0.69643 In|0.6875 2010|0.67857 in|0.66964 the|0.66071 United|0.65179 States|0.64286 an|0.63393 estimated|0.625 21|0.61607 880|0.60714 new|0.59821 cases|0.58929 were|0.58036 diagnosed|0.57143 and|0.5625 13|0.55357 850|0.54464 women|0.53571 died|0.52679 of|0.51786 ovarian|0.50893 cancer|0.5 Around|0.49107 1800|0.48214 of|0.47321 the|0.46429 new|0.45536 diagnoses|0.44643 were|0.4375 sex|0.42857 cord|0.41964 or|0.41071 stromal|0.40179 tumors|0.39286 11|0.38393 In|0.375 the|0.36607 United|0.35714 Kingdom|0.34821 as|0.33929 of|0.33036 2014|0.32143 approximately|0.3125 7|0.30357 000|0.29464 7|0.28571 100|0.27679 yearly|0.26786 diagnoses|0.25893 were|0.25 made|0.24107 and|0.23214 4|0.22321 200|0.21429 deaths|0.20536 occurred|0.19643 10|0.1875 16|0.17857 It|0.16964 is|0.16071 the|0.15179 5th|0.14286 most|0.13393 common|0.125 cancer|0.11607 in|0.10714 UK|0.098214 women|0.089286 Ovarian|0.080357 cancer|0.071429 is|0.0625 most|0.053571 commonly|0.044643 diagnosed|0.035714 after|0.026786 menopause|0.017857 16|0.0089286 |0",
			"previous_weights": " Ovarian|0 cancer|0.0075758 frequently|0.015152 recurs|0.022727 after|0.030303 treatment|0.037879 If|0.045455 a|0.05303 recurrence|0.060606 occurs|0.068182 in|0.075758 advanced|0.083333 disease|0.090909 it|0.098485 typically|0.10606 occurs|0.11364 within|0.12121 18|0.12879 months|0.13636 of|0.14394 initial|0.15152 treatment|0.15909 18|0.16667 months|0.17424 progression|0.18182 free|0.18939 survival|0.19697 Recurrences|0.20455 can|0.21212 be|0.2197 treated|0.22727 but|0.23485 the|0.24242 disease|0.25 free|0.25758 interval|0.26515 tends|0.27273 to|0.2803 shorten|0.28788 and|0.29545 chemoresistance|0.30303 increases|0.31061 with|0.31818 each|0.32576 recurrence|0.33333 10|0.34091 Low|0.34848 malignant|0.35606 potential|0.36364 tumors|0.37121 rarely|0.37879 relapse|0.38636 even|0.39394 when|0.40152 fertility|0.40909 sparing|0.41667 surgery|0.42424 is|0.43182 the|0.43939 treatment|0.44697 of|0.45455 choice|0.46212 15|0.4697 of|0.47727 LMP|0.48485 tumors|0.49242 relapse|0.5 after|0.50758 unilateral|0.51515 surgery|0.52273 in|0.5303 the|0.53788 previously|0.54545 unaffected|0.55303 ovary|0.56061 and|0.56818 they|0.57576 are|0.58333 typically|0.59091 easily|0.59848 treated|0.60606 with|0.61364 surgery|0.62121 More|0.62879 advanced|0.63636 tumors|0.64394 may|0.65152 take|0.65909 up|0.66667 to|0.67424 20|0.68182 years|0.68939 to|0.69697 relapse|0.70455 if|0.71212 they|0.7197 relapse|0.72727 at|0.73485 all|0.74242 and|0.75 are|0.75758 only|0.76515 treated|0.77273 with|0.7803 surgery|0.78788 unless|0.79545 the|0.80303 tumor|0.81061 has|0.81818 changed|0.82576 its|0.83333 histological|0.84091 characteristics|0.84848 or|0.85606 grown|0.86364 very|0.87121 quickly|0.87879 In|0.88636 these|0.89394 cases|0.90152 and|0.90909 when|0.91667 there|0.92424 is|0.93182 significant|0.93939 ascites|0.94697 chemotherapy|0.95455 may|0.96212 also|0.9697 be|0.97727 used|0.98485 14|0.99242 |1"
		}
	}
}
